We are live on ! Find out more
ECYT

Endocyte, Inc. Common Stock
ECYT

Delisted

ECYT was delisted on the 20th of December, 2018.

Back to rankings

2 hedge funds and large institutions have $1.45M invested in Endocyte, Inc. Common Stock in 2018 Q4 according to their latest regulatory filings, with 2 funds opening new positions, 0 increasing their positions, 0 reducing their positions, and 139 closing their positions.

New
Increased
Maintained
Reduced
Closed

99% less funds holding

Funds holding: 139 → 2 (-137)

99% less first-time investments, than exits

New positions opened: 2 | Existing positions closed: 139

100% less capital invested

Capital invested by funds: $1.11B → $1.45M (-$1.1B)

100% less funds holding in top 10

Funds holding in top 10: 8 → 0 (-8)

Holders
2
Holders Change
-137
Holders Change %
-98.56%
% of All Funds
0.04%
Holding in Top 10
–
Holding in Top 10 Change
-8
Holding in Top 10 Change %
-100%
% of All Funds
–
New
2
Increased
–
Reduced
–
Closed
139
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
OTC
Opera Trading Capital
France
+$1.31M

Top Sellers

Rank Fund Capital Flow
1
RCM
RA Capital Management
Massachusetts
-$110M
2
ACA
Avoro Capital Advisors
New York
-$94.2M
3
BlackRock
BlackRock
New York
-$93.7M
4
VMI
VHCP Management II
New York
-$74.8M
5
Vanguard Group
Vanguard Group
Pennsylvania
-$62.6M

ECYT Hedge Fund Activity: Q4 2018 in Review

2 of the 4,505 institutional investors tracked by Wall St. Rank reported a position in Endocyte, Inc. Common Stock (ECYT) for Q4 2018, worth a combined $1.45M — down 100% from $1.11B a quarter earlier.

Sellers outnumbered buyers: 139 funds closed out of ECYT and 2 opened new positions — a net loss of 137 holders — while 0 trimmed existing stakes and 0 added.

The largest buyer was Opera Trading Capital, opening a new position worth an estimated $1.31M. The largest seller was RA Capital Management, exiting entirely with an estimated $110M sold.

  • 2 institutional investors held Endocyte, Inc. Common Stock (ECYT) as of Q4 2018, down from 139 in Q3 2018.
  • Funds reported $1.45M of Endocyte, Inc. Common Stock stock for Q4 2018, down 100% quarter-over-quarter.
  • 2 funds opened new Endocyte, Inc. Common Stock positions in Q4 2018 and 139 closed out, a net change of -137 holders.
  • The largest Endocyte, Inc. Common Stock buyer in Q4 2018 was Opera Trading Capital, an estimated $1.31M added.
  • The largest Endocyte, Inc. Common Stock seller in Q4 2018 was RA Capital Management, an estimated $110M sold.

Based on aggregated 13F filings for Q4 2018.